JP2024543413A5 - - Google Patents
Info
- Publication number
- JP2024543413A5 JP2024543413A5 JP2024527604A JP2024527604A JP2024543413A5 JP 2024543413 A5 JP2024543413 A5 JP 2024543413A5 JP 2024527604 A JP2024527604 A JP 2024527604A JP 2024527604 A JP2024527604 A JP 2024527604A JP 2024543413 A5 JP2024543413 A5 JP 2024543413A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- ray powder
- pharmaceutical composition
- diffraction pattern
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21207942.0 | 2021-11-12 | ||
| EP21207942.0A EP4180428A1 (en) | 2021-11-12 | 2021-11-12 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
| PCT/US2022/049695 WO2023086564A1 (en) | 2021-11-12 | 2022-11-11 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543413A JP2024543413A (ja) | 2024-11-21 |
| JP2024543413A5 true JP2024543413A5 (cg-RX-API-DMAC10.html) | 2025-11-18 |
Family
ID=78617277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527604A Pending JP2024543413A (ja) | 2021-11-12 | 2022-11-11 | 結晶性イミダゾ[4,5-b]ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11814383B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4180428A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024543413A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118843624A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022387516A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3237156A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL312625A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024005766A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202334143A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023086564A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9067914B1 (en) * | 2013-12-10 | 2015-06-30 | Genzyme Corporation | Tropomyosin-related kinase (TRK) inhibitors |
| EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
| AU2024273547A1 (en) * | 2023-05-17 | 2025-12-04 | Centrexion Therapeutics Corporation | PARTICLES OF IMIDAZO [4,5-b] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| US9067914B1 (en) | 2013-12-10 | 2015-06-30 | Genzyme Corporation | Tropomyosin-related kinase (TRK) inhibitors |
| MA40698A3 (fr) | 2014-12-18 | 2020-01-31 | Genzyme Corp | Formulations pharmaceutiques d'inhibiteurs de kinase associée à la tropomyosine (trk) |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
| MX2021001957A (es) | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
| BR112022016901A2 (pt) * | 2020-02-26 | 2022-12-06 | Cullgen Shanghai Inc | Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso |
| EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
-
2021
- 2021-11-12 EP EP21207942.0A patent/EP4180428A1/en not_active Withdrawn
-
2022
- 2022-11-11 MX MX2024005766A patent/MX2024005766A/es unknown
- 2022-11-11 JP JP2024527604A patent/JP2024543413A/ja active Pending
- 2022-11-11 US US17/985,531 patent/US11814383B2/en active Active
- 2022-11-11 EP EP22893662.1A patent/EP4430043A4/en active Pending
- 2022-11-11 WO PCT/US2022/049695 patent/WO2023086564A1/en not_active Ceased
- 2022-11-11 TW TW111143263A patent/TW202334143A/zh unknown
- 2022-11-11 CA CA3237156A patent/CA3237156A1/en active Pending
- 2022-11-11 AU AU2022387516A patent/AU2022387516A1/en active Pending
- 2022-11-11 CN CN202280087913.4A patent/CN118843624A/zh active Pending
- 2022-11-11 IL IL312625A patent/IL312625A/en unknown
-
2023
- 2023-11-09 US US18/505,713 patent/US12291528B2/en active Active
-
2025
- 2025-04-22 US US19/185,943 patent/US20250250274A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102425226B1 (ko) | Jak 저해제를 포함하는 제약 조성물 | |
| JP5371790B2 (ja) | 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、5−ht3および5−ht1a活性を有する化合物としての1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジン | |
| TWI359128B (en) | New crystalline form v of agomelatine, a process f | |
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| EA031116B1 (ru) | КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ | |
| US20160143909A1 (en) | Pharmaceutical composition | |
| US9669003B2 (en) | Use of flavone and flavanone derivatives in preparation of sedative and hypnotic drugs | |
| JP2013014584A (ja) | アゴメラチンの新規な共結晶、その調製のための方法及びそれを含む医薬組成物 | |
| JP3726291B2 (ja) | 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法 | |
| EP3819298B1 (en) | Compound having trka inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient | |
| JP2014506602A5 (cg-RX-API-DMAC10.html) | ||
| JP2026041824A (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| CA3001850A1 (en) | Solabegron zwitterion and uses thereof | |
| TW202334143A (zh) | 結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途 | |
| WO2024024961A1 (ja) | 2(1h)-ピリジンイミン誘導体 | |
| JP2025506783A5 (cg-RX-API-DMAC10.html) | ||
| JP2004504390A (ja) | (r)−n−[5−メチル−8−(4−メチルピペラジン−1−イル)−1,2,3,4−テトラヒドロ−2−ナフチル]−4−モルホリノベンズアミドの新規な形態 | |
| JP2002505254A (ja) | パロキセチン塩 | |
| TW200838537A (en) | Substituted quinazolines | |
| TWI900603B (zh) | 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶 | |
| EP1163241B1 (en) | Zolpidem salts | |
| KR20150054860A (ko) | 포스파티딜이노시톨 3-키나아제 억제제의 정제 제형 | |
| KR20240056457A (ko) | 마크로사이클릭 아졸로피리딘 | |
| CN113795492A (zh) | 无定形pi3k抑制剂和包含其的药物组合物 | |
| JP2016522224A (ja) | ピロロキノリンキノンリチウム塩の結晶体及び調製方法と応用 |